A pheresis involves the collection of specific blood components, such as platelets, plasma, or peripheral blood stem cells, individually or in combination, with the remnants returned to the donor or patient. 1 During apheresis, anticoagulation is necessary to prevent coagulation and clotting in the apheresis circuit. Here, citrate is preferred, because of its safety and effectiveness viz-a-viz the alternative: heparin. 2 Acute metabolic effects of apheresis include hypocalcaemia, hypercalciuria, secondary hyperparathyroidism, hypomagnesemia, and metabolic alkalosis, all of which are attributed to ionized calcium-citrate complexes. [3] [4] [5] [6] For example, Silberstein and colleagues reported an 18% reduction in ionized calcium, a net calcium loss of 150 mg, and an acute 280% increase in parathyroid hormone (PTH) levels. 3 These acute serum PTH elevations, in turn, have been related to a reduction in 1,25-dihydroxyvitamin D and an increase in the bone turnover marker osteocalcin. 7, 8 These observations collectively call for speculations about the effect of apheresis on bone mineral health. It is noteworthy that reduced lumbar spine bone mineral density (BMD) was observed among apheresis donors in one study. 9 Recently, changes in bone turnover in response to a single citrate load at a dose similar to that used for plateletpheresis have also been described. 10, 11 However, in view of the long history of apheresis, surprisingly little is known about the risk of fractures among frequent apheresis donors. 12 Therefore, we took advantage of information on apheresis donations and the occurrence of fractures in a large cohort of blood donors to assess the association between the two.
METHODS

Data sources
Data on apheresis donations were extracted from the Scandinavian Donations and Transfusions database (SCANDAT2), a binational database of blood donation and transfusion activities that has been described in detail elsewhere. 13 In summary, the database was created from computerized registers maintained by Swedish and Danish blood banks since 1968 and 1981, respectively. After data collection and cleaning, the database was linked with nationwide population and health data registers using the unique national registration numbers available for all individuals in both countries. 14, 15 The database thus provides long-term follow-up of a large number of donors for a range of health outcomes, including hospital care, fractures, and surgery. We previously used this database to study the occurrence of a range of diseases in both blood donors and transfusion recipients. [16] [17] [18] [19] Because apheresis collection of blood units has only been practiced sporadically in Danish blood banks, the present analyses were restricted to Swedish data only.
Outcome ascertainment
Occurrence of fractures was ascertained from the Swedish patient register, which included data on inpatient care in Sweden during the entire study period and outpatient specialist health care since 2004. 20 The classification of fractures was based on the International Classification of Diseases, Revisions 9 and 10 (for specific codes, see Table  S1 , available as supporting information in the online version of this paper). The main outcome of interest was "all fractures," but we also specifically analyzed the occurrence of "osteoporosis-related fractures," which was defined a priori as fractures of the forearm, proximal humerus, proximal femur, and ankle. Tooth and patellar fractures were excluded from the analysis.
Study design and statistical analyses
From the SCANDAT2 database, we extracted all available data on Swedish blood donors who had performed at least one apheresis donation between 1990 and 2012, excluding autologous donations. Analyses were restricted to this relatively recent period to avoid the possibility that the results were influenced by suspected economic motivations for blood donation during earlier periods 16 and to avoid the effects of possible under-reporting of the numbers of apheresis procedures during the 1980s. 13 We conducted a retrospective analysis, following donors from the first recorded apheresis donation, in or after 1990, until death, emigration, or the end of follow-up (December 31, 2012), whichever occurred first. Within this follow-up interval, donors were followed for the fracture outcome of interest (i.e., any fracture or osteoporotic fractures). To count only mutually unrelated events, upon occurrence of a fracture in a donor, they would re-enter follow-up only after a 6-month waiting period.
In the main analyses, we assessed the effect of the total number of apheresis donations recorded during the study period, irrespective of the type of apheresis procedure. The cumulative number of apheresis donations was considered time-dependent, so that donors would move between categories with each successive donation. Because citrate exposure may differ between plasmapheresis and plateletpheresis procedures, we also considered the numbers of plasma and platelet apheresis donations separately. Because we hypothesized that the putative effects of the number of apheresis donations on the risk of fractures may have variable latency, we also assessed the number of donations performed in the most recent 2, 5, and 10 years. Again, this was done in a time-dependent manner by tracking the donation activity of all donors at every given time point during their follow-up. The relative risk of fractures, expressed as the incidence rate ratio (IRR) in relation to the number of apheresis donations, was estimated using Poisson regression. Analyses were adjusted for age (in 1-year categories), sex, calendar period of observation (in 1-year categories), and time since most recent apheresis donation. Separate analyses were conducted for the number of apheresis donations overall and for the three fixedlength exposure windows. Analyses were performed both for all donors combined and stratified by sex. We also performed analyses restricted to postmenopausal women (i.e., women aged 50 years), because we hypothesized that this group might be more susceptible to the negative effects of repeated perturbations in calcium homeostasis. All variables were treated as categorical. Trend tests were performed by fitting the variable for the number of apheresis donations as a linear term. Ninety-five percent confidence intervals (CIs) were constructed using Wald tests.
All data processing and statistical analyses were performed using the SAS statistical analysis software package (version 9.4; SAS Institute, Inc.), and p values < 0.05 were considered statistically significant.
Ethics
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RESULTS
After the exclusion of donors with only whole blood, autologous, or failed donations, 140,289 apheresis donors were included in the analyses. Of these, 67,970 (48%) were women. The mean age at first apheresis donation among female and male donors was 31.5 and 33.2 years, respectively. Most apheresis donations (3,100,849 donations; 95.7%), were plasma donations, as presented in Table 1 . The relative risks of fractures overall, and specifically of osteoporotic fractures, in relation to the cumulative number of apheresis donations are presented in Table 2 . There was no evidence of an association between the cumulative number of apheresis donations and the risk of fractures either when we considered fractures overall or when we specifically assessed osteoporosis-related fractures. Among donors in the most extreme exposure category-those who made 100 or more apheresis donations-the relative risk of fracture was 0.99 (95% CI, 0.92-1.06) for both sexes combined, 1.00 (95% CI, 0.89-1.12) for all women, 1.08 (95% CI, 0.94-1.24) for postmenopausal women, and 0.98 (95% CI, 0.90-1.07) for men compared with donors who made from 9 to 24 cumulative apheresis donations. Similar patterns emerged upon analyzing the group of donors that made fewer apheresis donations and when we analyzed osteoporosis-related fractures separately (Table 2) . We also detected no statistically significant trends when the number of apheresis donations was fitted as a linear term (data not shown). Table 3 presents the relative risks of fracture in relation to the number of apheresis donations in the most recent 2-year, 5-year, and 10-year windows. Again, there was no association between the number of apheresis (Table 3) . Again, trend tests revealed no conspicuous departure from the overall picture (data not shown). Finally, the results did not vary when analyses were repeated considering the number of plasma and platelet apheresis donations separately among the 135,259 and 11,345 donors who ever donated plasma and platelets, respectively (data not shown).
DISCUSSION
This is the first study to evaluate the long-term effects of frequent apheresis donation on fracture risk among healthy, voluntary donors. We find no association between frequent apheresis donation, during which donors have repeatedly been exposed to intravenous citrate anticoagulation, and the risk of fractures. Although acute perturbations in calcium metabolism after apheresis donation have been reported previously, 5, 21, 22 we provide evidence that such repeated acute effects among frequent apheresis donors do not cumulatively impact long-term fracture risk. Our study has several merits. It is based on a very large and unrestricted selection of voluntary, healthy apheresis donors who were followed over a long period. Furthermore, the study design, the well-defined cohort of over 140,000 apheresis donors with a broad age range, up to 23 years of follow-up, and the use of complete medical registers for the ascertainment of fractures make our results robust and the study adequately powered. However, we do acknowledge some potential weaknesses. Our investigation is an observational, register-based, recordlinkage study, in which we were unable to obtain more detailed data about fracture diagnoses for validation. However, although this could result both in some degree of misclassification and in the under-reporting of fractures, we believe that outcome misclassification should be minimal. Also, because the extent of this misclassification is unlikely to be related to previous apheresis donation frequency, it should not impact the validity of our observation. In addition, it has been demonstrated that the use of fracture coding is of high quality, particularly for hip fractures, which are mostly osteoporotic; and the specificity in the Swedish inpatient register reportedly is close to 100%.
14, 23 We also acknowledge that, in the current study, most apheresis donations were plasma, in which citrate exposure is less compared with other types of apheresis donations, because much of the citrate introduced into the extracorporeal circuit is not returned to the donor. 24 Nevertheless, evidence suggests that PTH surges occur even with very little exogenous citrate, supporting the interpretation of the present study. 25 Our study is limited by lack of data on other characteristics of interest, such as serum calcium, PTH, or BMD levels, which precluded us from providing a comprehensive description of shortterm and long-term metabolic changes among apheresis donors, but this was not the primary objective of the study. Our database also is limited by a lack of information on additional, potentially important covariates, such as smoking, body mass index, and other medication that could influence fracture risk, which could result in some degree of residual confounding for which we cannot account. Thus, it is possible that a deleterious association between apheresis donation and fracture risk was masked by a gradient of healthier behavior among the more frequent apheresis donors. Although we have no definitive data on these covariates, we do not believe this is the case given the complete lack of an association that we observed and the fact that we previously did not observe any clear associations between donation frequency and health outcomes. 26 Along the same lines, because all fractures were ascertained through the Swedish patient register, which has only recorded specialized outpatient care since 2004, fractures that would not necessitate surgery and/or hospital admission would not be captured before that date. As such, we likely underestimated the occurrence of less complicated fractures. However, because the degree of such under-reporting is very unlikely to differ between infrequent and frequent apheresis donors, it should only lead to a decreased power and should not affect relative estimates. A further limitation of the register-based design is the absence of data on actual citrate exposure, which unfortunately prevented us from accurate quantification of the association between citrate load and fracture risk and also did not allow us to provide data on a safe upper limit of citrate exposure. That said, because we observed no increased risks, even among those who made an average of at least eight apheresis donations per year over 10 years (with an upper CI of 1.04), current practices appear to be safe. The side effects of citrate infusion during apheresis are predominantly mild, transient, and most often self-limiting. Perioral or peripheral paresthesia secondary to hypocalcaemia is the most commonly observed side effect and is frequently reported. 10, 11 Severe effects, such as involuntary carpopedal spasm and progression to tetany, are rare but have been reported in a very small proportion (0.89%) of apheresis donors. 27 The aforementioned side effects are almost entirely related to the decreased ionized calcium levels associated with citrate anticoagulation, leading to secondary hyperparathyroidism. Such short-term alterations in calcium and phosphate balance have also been associated with lower vitamin D levels, and some have speculated that these alterations have long-term consequences on bone turnover, thereby increasing the risk of fracture. 28 To date, evidence of the long-term effects of these metabolic perturbations on bone turnover and fracture risk is almost entirely lacking. Several underlying mechanisms have been proposed that could contribute to elevated fracture risk among repeated apheresis donors, including: 1) repeated alterations in calcium-phosphate balance, and 2) recurring protein loss (particularly that related to bone homeostasis). 8 Our study demonstrates that long-term increased risks of fractures are unlikely in apheresis donors. Given that exposure to citrate during apheresis decidedly affects calcium homeostasis, at least transiently, several potential explanations for our observations of no long-term effects should be considered. Citrate-induced, acute, short-term elevations in PTH levels could exert an anabolic effect by increasing the number of osteoblasts, as proposed previously. 4, 7, 29 Although this may be a possible underlying mechanism, it requires further confirmation from large population studies. Some support for a possible anabolic effect of repeated PTH spikes triggered by apheresis donations comes from a pilot study of postmenopausal women by Boot and colleagues, who observed that BMD was slightly higher among repeated apheresis donors compared with whole blood donors, 9 thus demonstrating that such transient spurts have beneficial effects on bone. It is also possible that the cumulative citrate exposure experienced by the donors in this study was simply insufficient to have a detectable effect on fracture risk, or that a slightly increased risk was masked by a "healthy donor effect," that is, in which frequent donors had healthier behavior. 16, 26, 30 We also acknowledge that our results may have been influenced by calcium intake, because calcium supplementation is occasionally recommended for apheresis donors. However, although we have no specific data about this practice, it seems unlikely to have had a major effect, because, in that circumstance, the recommended calcium supplementation is only transient.
In conclusion, using a large database of blood donations, we observed no association between apheresis donations and fracture risk, suggesting that the repeated, acute metabolic alterations in calcium homeostasis among frequent donors do not influence the risk of fractures. Although our results indicate that frequent apheresis donors are unlikely to have an increased risk of fractures, they do not necessarily preclude prophylactic calcium supplementation and detailed evaluation for secondary hyperparathyroidism among these donors.
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